A phase II study of encorafenib and cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E-mutated metastatic colorectal cancer (mCRC).

作者
Anna Ceccarelli
出处
期刊:
摘要

Background: BRAF V600E mutation occurs in approximately 10% of metastatic colorectal cancers (mCRC) and confers poor prognosis. While the combination of encorafenib and cetuximab (EC) has demonstrated improved outcomes in previously treated BRAF V600E-mutated mCRC patients (pts), the duration of response remains suboptimal with median progression-free survival (mPFS) of 4.3 months (m). Approximately half of pts (45%) receive subsequent treatment after EC progression, predominantly with chemotherapy (ChT). Data from the safety lead-in (SLI) of the BREAKWATER trial, assessing EC in combination with ChT doublet in the first-line setting, demonstrated manageable safety profile and promising early efficacy signals for EC in combination with FOLFIRI, despite pharmacokinetic interaction. Methods: ECLYPse (NCT06640166; EU CT Number 2023-508615-24-00) is a multicenter, single-arm, phase II study evaluating EC continuation beyond progression in combination with FOLFIRI in pts with BRAF V600E-mutated mCRC who progressed on second-line EC. Key eligibility criteria include: histologically confirmed colorectal adenocarcinoma, BRAF V600E mutation, documented disease progression on EC in second-line setting, benefit to previous treatment with EC (best response: complete response, partial response or stable disease lasting for at least 3 months), measurable disease according to RECIST 1.1 criteria, ECOG PS ≤1, and availability of archival tumor tissue. Patients receive encorafenib 300 mg daily, cetuximab 500mg/m2 iv every 2 weeks, and standard FOLFIRI regimen. The primary endpoint is 6-month PFS rate. Secondary endpoints include PFS, overall survival, duration of response, objective response rate, disease control rate, and safety. Translational analyses include comprehensive genomic profiling on archival tissue and serial ctDNA analysis. Tumor assessment with contrast-enhanced CT scan of thorax, abdomen and pelvis is performed every 8 weeks. Using a single-stage design with one-sided α = 0.05 and 80% power, 25 patients will be enrolled to detect an improvement in 6-month PFS rate from 10% (null hypothesis) to 30% (alternative hypothesis). If at least 7 pts will be alive and not progressing at 6 months, the treatment will be considered sufficiently active to warrant further investigation. The study is currently enrolling at multiple sites in Italy. Clinical trial information: NCT06640166.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
李健的应助被阳光的半雪采纳,获得10
1秒前
风趣忻完成签到,获得积分20
1秒前
obito发布了新的文献求助10
1秒前
orixero的应助被噫吁嚱采纳,获得10
2秒前
2秒前
2秒前
yue完成签到,获得积分10
3秒前
3秒前
4秒前
5秒前
丘比特的应助被最好的采纳,获得10
5秒前
一杯芝士发布了新的文献求助10
6秒前
桐桐的应助被风中的宛白采纳,获得10
6秒前
6秒前
渣渣兔完成签到,获得积分10
6秒前
6秒前
张哈哈完成签到,获得积分10
6秒前
leye发布了新的文献求助10
6秒前
帕克完成签到,获得积分10
7秒前
实验室发布了新的文献求助10
7秒前
ZeKaWa的应助被健壮的大有采纳,获得10
7秒前
无限芸遥发布了新的文献求助10
7秒前
7秒前
帅斌完成签到,获得积分10
8秒前
syyy发布了新的文献求助10
8秒前
余漆完成签到,获得积分10
8秒前
阿斯顿风格完成签到,获得积分10
9秒前
9秒前
Vicktor2021完成签到,获得积分10
10秒前
吗喽发布了新的文献求助10
11秒前
12秒前
12秒前
syyy完成签到,获得积分10
13秒前
13秒前
ssc完成签到,获得积分10
14秒前
mmol发布了新的文献求助10
14秒前
null完成签到,获得积分0
14秒前
风趣忻发布了新的文献求助10
14秒前
赘婿的应助被流苏采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651